DGAP Post-admission Duties announcement: CompuGroup Medical SE & Co. KGaA / Share Buy-back 
CompuGroup Medical SE & Co. KGaA: Continuation of the Share Buy-Back Program 
2021-03-25 / 21:47 
Dissemination of a Post-admission Duties announcement transmitted by DGAP - a service of EQS Group AG. 
The issuer is solely responsible for the content of this announcement. 
=---------------------------------------------------------------------------------------------------------------------- 
Disclosure pursuant to Article 5(1)(a) of Regulation (EU) No 596/2014 and Article 3(1) of Commission Delegated 
Regulation (EU) No 2016/1052 
Continuation of the Share Buy-Back Program 
Koblenz, March 25, 2021 - The increased share buy-back program announced by CompuGroup Medical SE & Co. KGaA (the 
"Company") in the ad-hoc release of March 25, 2021 will be continued in the period from March 26, 2021 until and 
including May 5, 2021 with the increased volume. With the extension of the share buy-back, the Company is again making 
use of the authorization granted by the annual general meeting of May 15, 2019 to purchase treasury shares pursuant to 
section 71(1) no. 8 of the German Stock Corporation Act (Aktiengesetz) in order to buy back an additional number of up 
to 500,000 shares of the Company at a total purchase price of up to EUR 38,000,000.00. Including the extension of the 
program the total volume of the share buy-back program is up to 1,000,000 shares of the Company (corresponding to 
approx. 1.86% of the Company's share capital) at a total purchase price (excluding transaction costs) of up to EUR 
73,000,000.00 in total (the "Share Buy-Back Program"). 
The Share Buy-Back Program will continue to be carried out by a credit institution. The credit institution will acquire 
the shares on the stock market and will decide on the timing of acquisitions independently of the Company and in 
accordance with the safe harbor provisions of Article 5 of Regulation (EU) No 596/2014 of the European Parliament and 
of the Council of 16 April 2014 (Market Abuse Regulation) in conjunction with the Commission Delegated Regulation (EU) 
2016/1052 of 8 March 2016. In addition, the purchase price per share (excluding transaction costs) paid must not 
exceed, or fall short of, the volume-weighted average price of the Company's share in XETRA (or a functionally 
comparable successor system replacing the XETRA system) trading on the Frankfurt Stock Exchange during the last five 
trading days before the acquisition date by more than 10%. 
The acquired treasury shares in CompuGroup Medical SE & Co. KGaA are to be used for purposes permitted under the 
authorization granted by the annual general meeting of May 15, 2019, in particular for servicing the existing stock 
option plans of the Company as well as the utilization as acquisition currency. 
The share buy-back via XETRA on the Frankfurt Stock Exchange terminates at the end of April 30, 2021, 24:00 hrs (CEST). 
To the extent shares in CompuGroup Medical SE & Co. KGaA shall be bought back during a closed period within the meaning 
of Article 19(11) of Regulation (EU) No 596/2014 of the European Parliament and of the Council of April 16, 2014 or 
during a period in which CompuGroup Medical SE & Co. KGaA resolved to delay the disclosure of inside information in 
accordance with Article 17(4) of Regulation (EU) No 596/2014 of the European Parliament and of the Council of April 16, 
2014, CompuGroup Medical SE & Co. KGaA has continuously appointed a credit institution for the execution of these 
buy-backs, which will make its decisions concerning the timing of the acquisitions of the shares in CompuGroup Medical 
SE & Co. KGaA - in compliance with contractual obligations - independently of, and without influence by, CompuGroup 
Medical SE & Co. KGaA in accordance with Article 4(2)(b) of Commission Delegated Regulation (EU) No 2016/1052 of March 
8, 2016. CompuGroup Medical SE & Co. KGaA will not influence the decisions of the credit institution in this respect. 
The Share Buy-Back Program will be continue to be carried out in accordance with the safe harbor provision pursuant to 
Article 5 of Regulation (EU) No 596/2014 of the European Parliament and of the Council of April 16, 2014 and the 
provisions of Commission Delegated Regulation (EU) 2016/1052 of March 8, 2016 and on the basis of the aforementioned 
authorization of the general meeting of CompuGroup Medical SE & Co. KGaA of May 15, 2019. CompuGroup Medical SE & Co. 
KGaA also imposed corresponding obligations on the credit institution appointed by the Company for purchasing shares in 
the Company. 
The shares in CompuGroup Medical SE & Co. KGaA will be purchased at market prices in accordance with the conditions for 
trading pursuant to Article 3 of Commission Delegated Regulation (EU) 2016/1052 of March 8, 2016. In particular, the 
shares in CompuGroup Medical SE & Co. KGaA will not be purchased at a price higher than the higher of the price of the 
last independent trade or the highest current independent purchase bid on the trading venue where the purchase is 
carried out. In addition, CompuGroup Medical SE & Co. KGaA will not purchase on any trading day more than 25% of the 
average daily volume of the shares on the trading venue on which the purchase is carried out. The average daily volume 
of shares is calculated on the basis of the average daily volume traded during the 20 trading days preceding the 
relevant date of purchase. 
Furthermore, the Share Buy-Back Program may be suspended and also resumed at any time, to the extent necessary and 
permitted by law. 
Information on transactions relating to the Share Buy-Back Program (both before and after the change) will be 
adequately disclosed no later than by the end of the seventh trading day following the date of execution of such 
transactions in a detailed form and in an aggregated form. In addition, CompuGroup Medical SE & Co. KGaA will post the 
disclosed transactions on its website (www.cgm.com) and ensure that the information is kept available to the public for 
at least five years from the date of disclosure. 
End 
Disclaimer: 
This publication contains forward-looking statements. These statements are based on the current views, expectations and 
assumptions of, and information available to, the management of CompuGroup Medical SE & Co. KGaA. Forward-looking 
statements do not provide a guarantee of the occurrence of future results and developments and involve known and 
unknown risks and uncertainties. Various factors may cause actual future results, developments or events to differ 
materially from those described in these statements. Neither CompuGroup Medical SE & Co. KGaA nor any other person 
assumes any responsibility whatsoever for the accuracy of the views expressed in this publication or the assumptions on 
which they are based. CompuGroup Medical SE & Co. KGaA assumes no obligation to update the forward-looking statements 
contained in this publication. 
Koblenz, March 25, 2021 
CompuGroup Medical SE & Co. KGaA 
The general partner 
Contact: 
Investor Relations 
Phone +49 261 8000 7030 
Email: investor@cgm.com 
=---------------------------------------------------------------------------------------------------------------------- 
2021-03-25 The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press 
Releases. 
Archive at www.dgap.de 
=---------------------------------------------------------------------------------------------------------------------- 
Language:     English 
Company:      CompuGroup Medical SE & Co. KGaA 
              Maria Trost 21 
              56070 Koblenz 
              Germany 
Internet:     www.cgm.com 
 
End of News   DGAP News Service 
=------------

1178723 2021-03-25

(END) Dow Jones Newswires

March 25, 2021 16:47 ET (20:47 GMT)